SL65.0155

SL65.0155 is a selective 5-HT4 receptor partial agonist (Ki = 0.6 nM; IA = 40-50% (relative to 5-HT)). It potently enhances cognition, learning, and memory,    and also possesses antidepressant effects. SL65.0155 was in phase II clinical trials around 2004-2006 for the treatment of memory deficits and dementia but no new information has surfaced since and it appears to have been abandoned.